Содержание
- 2. Disclaimer This document was prepared by Hemoglobin Oxygen Therapeutics LLC (“HbO2 Therapeutics” or the “Company”) to
- 3. Mission Statement To develop and commercialize the first and best in class technology platform for oxygen-carrying
- 4. Company at a Glance Delaware registered in 2014, technology is going back to 1990s with $1
- 5. Brian Dawson Senior Director, Process Development 25 years experience in development & commercialization of HbO2’s products
- 6. Hemopure and Oxyglobin HBOCs with unique efficacy and safety profiles…
- 7. Worldwide blood shortage COVID-19 pandemic highlights the need for a product that can successfully substitute blood’s
- 8. Strategic National Stockpiles Out-of-hospital / Ambulance services Remote locations / Military battlefield use Prehospital trauma (military
- 9. Blood Is Not An Option Blood disorders including Sickle Cell disease, Hemolytic Anemia, etc. Rare blood
- 10. Blood shortage, a similar issue in veterinary markets 2 million canine transfusions are needed annually in
- 11. ZK1 Nutrients There is a constant demand for donated organs Organ eligibility criteria are extremely severe
- 12. Additional indications include… Ischemia indications including Minimization of infarct size (STEMI - ST-Elevation myocardial infarction) Resuscitation
- 13. Robust Pipeline
- 14. Strong value creating recent progress US Department of Defense signed and sponsored Hemopure trial for pre-hospital
- 15. Strong value creating milestones FDA submission for Hemopure Phase 3 pivotal BNO clinical trial Start of
- 16. Major academic & health centers collaborations
- 17. Expanded access program hospitals
- 18. Over 300 peer-reviewed publications
- 19. Characteristics of Hemopure Hb concentration 13 g/dL Plasma half-life ~ 19 hours Size = ~ 1
- 20. Relative Efficacy to Increase Total Hb Impact of 250 mL : PRBCs > whole blood, >
- 21. Vital Organ Blood Flow MAP responds to Hemopure; ↑ 10 – 20 mmHg Vital organ blood
- 22. Tissue Oxygenation Vital Organ Oxygenation Maintained Hemodilution carried out in 3 stages: 10%, 30%, 50% Organ-specific
- 23. Expanded Access Real World Clinical Experience Representative Cases Three sickle cell patients in crisis: RBCs refused/unavailable
- 24. Ex-situ Perfusion prior to Transplantation Transplantation of high-risk donor livers after ex situ resuscitation and assessment
- 25. Manufacturing capacities Facility building is fully constructed Stage I is in place and operational ($20m replacement
- 26. Cash positive in 2023 with $50m investment $20m commitment secured
- 28. Скачать презентацию